OGN stock · PATH stock

OGN vs PATH

Organon & Co (OGN) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.

Organon & Co (OGN) is a drug manufacturers - general company listed on US.

Uipath Inc (PATH) is a software - infrastructure company listed on US.

Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.

Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.

OGN currently screens at market cap $2.52B and trailing P/E 3.4. PATH currently screens at market cap $6.07B and trailing P/E 19.4.

Not investment advice. Open the OGN and PATH stock pages for the full models.

Not investment advice.

Popular Stock Comparisons